<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109421">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02108964</url>
  </required_header>
  <id_info>
    <org_study_id>CEGF816X2101</org_study_id>
    <nct_id>NCT02108964</nct_id>
  </id_info>
  <brief_title>A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies</brief_title>
  <official_title>A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the maximum tolerated dose (MTD) or recommended dose for expansion (RDE) of
      EGF816 and to investigate the anti-tumor activity of EGF816
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Phase I Part: Incidence of dose limiting toxicity (DLT)</measure>
    <time_frame>first 28 days of dosing</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Maximum tolerated dose/Recommended dose for expansion (MTD)/RDE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Part: Overall response rate (ORR)</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>ORR (Overall respnse rate ). Overall respnse rate is the proportion of patients with a best overall response of complete response (CR) or partial respose (PR) according to RECIST 1.1 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best overall response</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best overall response (BOR). BOR is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Progression-free survival (PFS). PFS is the time from date of randomization/start of treatment to the date of event defined as the first documented progression or death due to any cause according to RECIST 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>baseline, every 8 weeks until disease progression, consent withdraw or death  up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Duration of response (DOR). For patients with a CR or PR (which may have to be confirmed the start date is the date of first documented response (CR or PR) and the end date and censoring is defined the same as that for time to progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of adverse events (AEs)</measure>
    <time_frame>continuously during study until 30 days after safety follow up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize EGF816 as a measure of safety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics properties of EGF816 and metabolite LMI258</measure>
    <time_frame>cycle 1 day 1,2,8, 15; cycle 2 day 1, 2; cycle 3 day 1; cycle 4 day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma concentration vs. time profiles, plasma PK parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the tumor EGFR signaling inhibition by EGF816</measure>
    <time_frame>baseline and cycle 1 day 15</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pre- and post- treatment immunohistochemistry of EGFR pathway molecules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Dose interruptions and reductions</measure>
    <time_frame>continuously throughout the study until 30 days after safety follow up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize the EGF816 as a measure of tolerability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency/severity of serious adverse events (SAEs)</measure>
    <time_frame>continuously during study until 30 days after safety follow up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To characterize EGF816 as a measure of safety</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">211</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Phase I part</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>at least 21 patients with EGFR mutations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II part arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients must have advanced NSCLC with EGFR mutation (L858R or ex19del, not T790M)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II part arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients must have advanced NSCLC with an acquired T790M EGFR mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II part arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>80 patients must have advanced NSCLC with a &quot;de novo&quot; T790M EGFR mutation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II part arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 patients must have an advanced solid tumor harboring any EGFR mutation; and NOT be otherwise eligible for groups 1-3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <description>EGF816 will be dosed once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take EGF816 exactly as prescribed.</description>
    <arm_group_label>Phase I part</arm_group_label>
    <arm_group_label>Phase II part arm 1</arm_group_label>
    <arm_group_label>Phase II part arm 2</arm_group_label>
    <arm_group_label>Phase II part arm 3</arm_group_label>
    <arm_group_label>Phase II part arm 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Written informed consent must be obtained prior to any screening procedures

        Phase I part only:

        - Patient must have an advanced solid tumor with any documented EGFR mutation.

        Phase II part only:

          -  Group 1: patients must have advanced NSCLC with EGFR mutation (L858R or ex19del, not
             T790M)

          -  Group 2: patients must have advanced NSCLC with an acquired T790M EGFR mutation

          -  Group 3: patients must have advanced NSCLC with a &quot;de novo&quot; T790M EGFR mutation.

          -  Group 4: patients must have an advanced solid tumor  harboring any EGFR mutation; and
             NOT be otherwise eligible for groups 1-3

          -  ECOG performance status ≤ 2

          -  Presence of at least one measurable lesion according to RECIST v1.1

        Exclusion Criteria:

        Phase I part only:

        - Patient have received more than 3 previousanti-neoplastic therapies in the advanced
        setting

        Phase II part only:

          -  Group 1:More than total of 3 previous anti-neoplastic treatments in the advanced
             setting

          -  Group 2: More than total of 2 previous anti-neoplastic therapies in the advanced
             setting

          -  Group 3: More than total of 2 previous anti-neoplastic therapies in the advanced
             setting

          -  Group 4: More than total of 3 previous anti-neoplastic treatments in the advanced
             setting.

          -  Patients with brain metastases

          -  Any medical condition that would, in the investigator's judgment, prevent the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures.

          -  Patient have out of range laboratory values defined as

               -  Bone marrow function

               -  Absolute Neutrophil Count (ANC) &lt;1.5 x 109/L

               -  Hemoglobin (Hgb) &lt;9 g/dL

               -  Platelets &lt;100 x 109/L

               -  Hepatic and renal function

               -  Total bilirubin &gt;1.5 x upper limit of normal (ULN). For patients with Gilbert's
                  syndrome total bilirubin &gt;2.5 x upper limit of normal (ULN).

               -  Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) &gt;3 x ULN

          -  Patients with tumor involvement of the liver must have AST and/or ALT &gt;5 x ULN

             • Serum creatinine &gt;1.5 x ULN and/or measured creatinine clearance &lt; 75% LLN

          -  Patients receiving treatment with medications that are known to be 1) strong
             inhibitors or inducers of CYP3A4/5; 2) CYP2D6 substrate with narrow therapeutic index
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 7, 2014</lastchanged_date>
  <firstreceived_date>April 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC,</keyword>
  <keyword>EGFRmut -TKI,</keyword>
  <keyword>EGF816,</keyword>
  <keyword>EGFRmut solid malignancies</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
